Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Accumulated Expenses (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Accumulated Expenses for 11 consecutive years, with $9.5 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses fell 21.35% to $9.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.5 million through Dec 2025, down 21.35% year-over-year, with the annual reading at $9.5 million for FY2025, 21.35% down from the prior year.
  • Accumulated Expenses for Q4 2025 was $9.5 million at Cartesian Therapeutics, up from $7.7 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $15.6 million in Q4 2023, with the low at $6.8 million in Q1 2021.
  • Average Accumulated Expenses over 5 years is $10.6 million, with a median of $10.0 million recorded in 2021.
  • The sharpest move saw Accumulated Expenses soared 39.56% in 2022, then plummeted 30.69% in 2024.
  • Over 5 years, Accumulated Expenses stood at $10.5 million in 2021, then soared by 33.71% to $14.1 million in 2022, then grew by 10.57% to $15.6 million in 2023, then decreased by 22.45% to $12.1 million in 2024, then fell by 21.35% to $9.5 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $9.5 million, $7.7 million, and $8.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.